Management of the behavioral aspects of Parkinson’s disease

References

• Cummings JL. Depression and Parkinson’s disease: a review. Am. J. Psychiatry149, 443–454 (1992).
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Gold M, Chari G, Hauser RA. Current issues in depression in Parkinson’s disease. Am. J. Geriatr. Psychiatry7, 110–118 (1999).
   PubMed Web of Science ®Google Scholar
• Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson’s disease. Arch. Neurol.53, 175–179 (1996).
   PubMed Web of Science ®Google Scholar
• Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat. Disord.8, 193–197 (2002).
   PubMed Web of Science ®Google Scholar
• Henderson R, Kurlan R, Kersun JM, Como P. Preliminary examination of the comorbidity of anxiety and depression in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci.4, 257–264 (1992).
   PubMed Web of Science ®Google Scholar
• Gotham AM, Brown RG, Marsden CD. Depression in Parkinson’s disease: a quantitative and qualitative analysis. J. Neurol. Neurosurg. Psychiatry49, 381–389 (1986).
   PubMed Web of Science ®Google Scholar
• Mayeux R, Stern Y, Cote L, Williams JB. Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology34, 642–646 (1984).
   PubMed Web of Science ®Google Scholar
• Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J. Neuropathol. Exp. Neurol.50, 743–755 (1991).
   PubMed Web of Science ®Google Scholar
• Mayberg HS, Starkstein SE, Sadzot B et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann. Neurol.28, 57–64 (1990).
   PubMed Web of Science ®Google Scholar
• Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks D. Brain serotonin 5HT1A receptors in Parkinson’s disease with and without depression measured by positron emission tomography with 11C-WAY 10635. Mov. Disord.15, 213 (2000).
   Google Scholar
• Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain128, 1314–1322 (2005).
   PubMed Web of Science ®Google Scholar
• Takeshita S, Kurisu K, Trop L, Arita K, Akimitsu T, Verhoeff NP. Effect of subthalamic stimulation on mood state in Parkinson’s disease: evaluation of previous facts and problems. Neurosurg. Rev.28, 179–186 (2005).
   PubMed Web of Science ®Google Scholar
• Cole SA, Woodard JL, Juncos JL, Kogos JL, Youngstrom EA, Watts RI. Depression and disability in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci.8, 20–25 (1996).
   PubMed Web of Science ®Google Scholar
• Kostic VS, Filipovic SR, Lecic D, Momcilovic D, Sokic D, Sternic N. Effect of age at onset on frequency of depression in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry57, 1265–1267 (1994).
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry55, 377–382 (1992).
   PubMed Web of Science ®Google Scholar
• Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J. Neurol. Neurosurg. Psychiatry69, 308–312 (2000).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J. Am. Geriatr. Soc.52, 784–788 (2004).
   PubMed Web of Science ®Google Scholar
• Kuopio A, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson’s disease. Mov. Disord.15, 216–223 (2000).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Morales KH, Moberg PJ et al. Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov. Disord.20, 1161–1169 (2005).
   PubMed Web of Science ®Google Scholar
• Miyasaki JM, Shannon K, Voon V et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson’s disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology66, 996–1002 (2006).
   PubMed Web of Science ®Google Scholar
• Oxman TE, Sengupta A. Treatment of minor depression. Am. J. Geriatr. Psychiatry10, 256–264 (2002).
   PubMed Web of Science ®Google Scholar
• Menza MA, Marin H, Kaufman K, Mark M, Lauritano M. Citalopram treatment of depression in Parkinson’s disease: the impact on anxiety, disability, and cognition. J. Neuropsychiatry Clin. Neurosci.16, 315–319 (2004).
   PubMed Web of Science ®Google Scholar
• Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F. The SSRI, citalopram, improves bradykinesia in patients with Parkinson’s disease treated with L-dopa. Clin. Neuropharmacol.25, 21–24 (2002).
   PubMed Web of Science ®Google Scholar
• Dell’Agnello G, Ceravolo R, Nuti A et al. SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin. Neuropharmacol.24, 221–227 (2001).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease. Mov. Disord.12, 756–759 (1997).
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Nuti A, Piccinni A et al. Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology55, 1216–1218 (2000).
   PubMed Web of Science ®Google Scholar
• Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov. Disord.15, 986–989 (2000).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Taraborelli D, Morales KH, Duda JE, Katz IR, Stern MB. Escitalopram for major depression in Parkinson’s disease: an open-label flexible dosage study. J. Neuropsychiatry Clin. Neurosci.18, 377–383 (2006).
   PubMed Web of Science ®Google Scholar
• Wermuth L, Sorensen P, Timm S et al. Depression in idiopathic Parkinson’s disease treated with citalopram. Nord. J. Psychiatry52, 163–169 (1998).
   Web of Science ®Google Scholar
• Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR. SSRIs in the treatment of depression in Parkinson’s disease. Int. J. Geriatric Psychiatry18, 552–554 (2003).
   PubMed Web of Science ®Google Scholar
• Simons JA. Fluoxetine in Parkinson’s disease. Mov. Disord.11, 581–582 (1996).
   PubMed Web of Science ®Google Scholar
• Steur EN. Increase of Parkinson disability after fluoxetine medication. Neurology43, 211–213 (1993).
   PubMed Web of Science ®Google Scholar
• Jiménez-Jiménez FJ, Tejeiro J, Martinez-Junquera G, Cabrera-Valdivia F, Alarcon J, Garcia-Albea E. Parkinsonism exacerbated by paroxetine. Neurology44, 2406 (1994).
   PubMed Web of Science ®Google Scholar
• Gony M, Lapeyre-Mestre M, Montastrue JL. Risk of serious extrapyramidal symptoms in patients with Parkinson’s disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin. Neuropharmacol.26, 142–145 (2003).
   PubMed Web of Science ®Google Scholar
• Richard IH, Kurlan R, Tanner C et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Neurology48, 1070–1077 (1997).
   PubMed Web of Science ®Google Scholar
• Rihmer Z, Satori M, Pestality P. Selegiline–citalopram combination in patients with Parkinson’s disease and major depression. Inter. J. Psych. Clin. Pract.4, 123–125 (2000).
   PubMedGoogle Scholar
• Serrano-Duenas M. [A comparison between low doses of amitriptyline and low doses of fluoxetine in the control of depression in patients suffering from Parkinson’s disease]. Rev. Neurol.35, 1010–1014 (2002).
   PubMed Web of Science ®Google Scholar
• Antonini A, Tesei S, Zecchinelli A et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effects on quality of life. Mov. Disord.21, 1119–1122 (2006).
   PubMed Web of Science ®Google Scholar
• Andersen J, Aabro E, Gulman N, Helmsted A, Pedersen H. Antidepressive treatment in Parkinson’s disease. A controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-Dopa. Acta Neurol. Scand.62, 210–219 (1980).
   PubMed Web of Science ®Google Scholar
• Allain H, Cougnard J, Neukirch HC. Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT). Acta Neurol. Scand. (Suppl. 136), 73–78 (1991).
   Google Scholar
• Baronti F, Davis TL, Boldry RC, Mouradian MM, Chase TN. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology42, 541–544 (1992).
   PubMedGoogle Scholar
• Jouvent R, Abensour P, Bonnet AM, Widlocher D, Agid Y, Lhermitte F. Antiparkinsonian and antidepressant effects of high doses of bromocriptine. An independent comparison. J. Affect. Disord.5, 141–145 (1983).
   PubMedGoogle Scholar
• Rektorova I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur. J. Neurol.10, 399–406 (2003).
   PubMed Web of Science ®Google Scholar
• Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J. Neurol.253, 601–607 (2006).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tanner CM, Klawans HL. Buproprion in Parkinson’s disease. Neurology34, 1092–1094 (1984).
   PubMed Web of Science ®Google Scholar
• Avila A, Cardona X, Martin-Baranera M, Maho P, Sastre F, Bello J. Does nefazodone improve both depression and Parkinson’s disease? A pilot randomized trial. J. Clin. Psychopharmacol.23, 509–513 (2003).
   PubMed Web of Science ®Google Scholar
• Lemke MR. Effect of reboxetine on depression in Parkinson’s disease patients. J. Clin. Psychiatry63, 300–304 (2002).
   PubMed Web of Science ®Google Scholar
• Di Rocco A, Rogers JD, Brown R, Werner P, Bottiglieri T. S-adenosyl-methionine improves depression in patients with Parkinson’s disease in an open-label clinical trial. Mov. Disord.15, 1225 (2000).
   PubMedGoogle Scholar
• Aarsland D, Larsen JP, Waage O, Langeveld JH. Maintenance of electroconvulsive therapy for Parkinson’s diseae. Convuls. Ther.13, 274–277 (1997).
   PubMedGoogle Scholar
• Moellentine C, Rummans T, Ahlskog JE et al. Effectiveness of ECT in patients with parkinsonism. J. Neuropsychiatry Clin. Neurosci.10, 187–193 (1998).
   PubMed Web of Science ®Google Scholar
• Dreisig H, Beckmann J, Wermuth L, Skovlund S, Bech P. Psychologic effects of structured cognitive psychotherapy in young patients with Parkinson’s disease: a pilot study. Nord. J. Psych.53, 217–221 (1999).
   Web of Science ®Google Scholar
• Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor and levodopa-induced dyskinesias. Neurology53, 1154 (1999).
   PubMed Web of Science ®Google Scholar
• Gordon PH, Pullman SL, Louis ED, Furcht SJ, Fahn S. Mirtazapine in Parkinsonian tremor. Parkinsonism Relat. Disord.9, 125–126 (2002).
   PubMedGoogle Scholar
• Weintraub D, Oehlberg KA, Katz IR, Stern MB. Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson’s disease. Am. J. Geriatric Psychiatry14, 169–175 (2006).
   PubMed Web of Science ®Google Scholar
• Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety disorders in patients with Parkinson’s disease. Am. J. Psychiatry147, 217–220 (1990).
   PubMed Web of Science ®Google Scholar
• Vazquez A, Jiménez-Jiménez FJ, Garcia-Ruiz P, Garcia-Urra D. “Panic attacks” in Parkinson’s disease: a long-term complication of levodopa therapy. Acta Neurol. Scand.87, 14–18 (1993).
   PubMed Web of Science ®Google Scholar
• Richard IH. Anxiety disorders in Parkinson’s disease. Adv. Neurol.96, 42–55 (2005).
   PubMedGoogle Scholar
• Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson’s disease and anxiety: comorbidity with depression. Biol. Psychiatry34, 465–470 (1993).
   PubMed Web of Science ®Google Scholar
• Shiba M, Bower JH, Maraganore DM et al. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov. Disord.15, 669–677 (2000).
   PubMed Web of Science ®Google Scholar
• Siemers ER, Shekhar A, Quaid K, Dickson H. Anxiety and motor performance in Parkinson’s disease. Mov. Disord.8, 501–506 (1993).
   PubMed Web of Science ®Google Scholar
• Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose–response relationship of levodopa with mood and anxiety in fluctuating Parkinson’s disease: a double-blind, placebo-controlled study. Neurology45, 1757–1760 (1995).
   PubMed Web of Science ®Google Scholar
• Fetoni V, Soliveri P, Monza D, Testa D, Girotti F. Affective symptoms in multiple system atrophy and Parkinson’s disease: response to levodopa therapy. J. Neurol. Neurosurg. Psychiatry66, 541–544 (1999).
   PubMed Web of Science ®Google Scholar
• Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol.17, 73–82 (1994).
   PubMed Web of Science ®Google Scholar
• Heinrichs N, Hoffman EC, Hofmann SG. Cognitive–behavioral treatment for social phobia in Parkinson’s disease: a single-case study. Cogn. Behav. Pract.8, 328–335 (2001).
   PubMedGoogle Scholar
• Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain123, 733–745 (2000).
   PubMed Web of Science ®Google Scholar
• Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry70, 734–738 (2001).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson’s disease: a community-based study. Arch. Neurol.56, 595–601 (1999).
   PubMed Web of Science ®Google Scholar
• Graham JM, Grunewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry63, 434–440 (1997).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of “benign hallucinations” in Parkinson’s disease. Arch. Neurol.63, 713–716 (2006).
   PubMed Web of Science ®Google Scholar
• Dewey RB Jr, O’Suilleabhain PE. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson’s disease. Neurology55, 1753–1754 (2000).
   PubMed Web of Science ®Google Scholar
• Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson’s disease: drug induced psychiatric states. Adv. Neurol.65, 115–118 (1995).
   PubMedGoogle Scholar
• Chou KL, Messing S, Oakes D et al. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin. Neuropharmacol.28, 215–219 (2005).
   PubMed Web of Science ®Google Scholar
• Scholz E, Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonian patients with clozapine and fluperlapine. Eur. Arch. Psych. Neurol. Sci.235, 60–64 (1985).
   PubMedGoogle Scholar
• Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov. Disord.15, 201–211 (2000).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N. Engl. J. Med.340, 757–763 (1999).
   PubMed Web of Science ®Google Scholar
• Pollak P, Tison F, Rascol O et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomized, placebo-controlled study with open follow up. J. Neurol. Neurosurg. Psychiatry75, 689–695 (2004).
   PubMed Web of Science ®Google Scholar
• Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson’s disease. Mov. Disord.5, 225–229 (1990).
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Friedman JH, Lansang MC, Factor SA, Molho ES, Coskun DJ. Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Parkinsonism Relat. Disord.10, 439–441 (2004).
   PubMed Web of Science ®Google Scholar
• [No authors listed] Clozapine: new preparation. A last resort for parkinsonian patients with psychosis. Prescrire Int.11, 1–6 (2002).
   Google Scholar
• Morgante L, Epifanio A, Spina E et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin. Neuropharmacol.27, 153–156 (2004).
   PubMed Web of Science ®Google Scholar
• Klein C, Prokhhovor T, Miniovich A, Dobronevsky E, Rabey JM. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson’s disease psychosis. Clin. Neuropharmacol.29, 215–219 (2006).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Tinter R, Vuong KD, Lai D, Ringholz G. Double-blind, placebo-controlled unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov. Disord.20, 958–963 (2005).
   PubMed Web of Science ®Google Scholar
• Rabey JM, Prokhorov T, Miniovich A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 month’s duration. Mov. Disord.22, 313–318 (2006).
   Web of Science ®Google Scholar
• Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin. Neuropharmacol.29, 331–337 (2006).
   PubMed Web of Science ®Google Scholar
• Ford B, Lynch T, Greene P. Risperidone in Parkinson’s disease. Lancet344, 681 (1994).
   PubMed Web of Science ®Google Scholar
• Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J. Clin. Psychiatry56, 556–559 (1995).
   PubMed Web of Science ®Google Scholar
• Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson’s disease: an open pilot trial. Mov. Disord.15, 1230–1237 (2000).
   PubMed Web of Science ®Google Scholar
• Meco G, Alessandria A, Bonifati V, Giustini P. Risperidone for hallucinations in levodopa-treated Parkinson’s disease patients. Lancet343, 1370–1371 (1994).
   PubMed Web of Science ®Google Scholar
• Wolters EC, Jansen EN, Tuynman- Qua HG, Bergmans PL. Olanzapine in the treatment of dompaminomimetic psychosis in patients with Parkinson’s disease. Neurology47, 1085–1087 (1996).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov. Disord.17, 1031–1035 (2002).
   PubMed Web of Science ®Google Scholar
• Breier A, Sutton VK, Feldman PD et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol. Psychiatry52, 438–445 (2002).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology55, 789–794 (2000).
   PubMed Web of Science ®Google Scholar
• Lopez del Val LJ, Santos S. [Quetiapine and ziprasidone in the treatment of the psychotic disorders in Parkinson’s disease]. Rev. Neurol.39, 661–667 (2004).
   PubMedGoogle Scholar
• Gomez-Esteban JC, Zarranz JJ, Velasco F et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin. Neuropharmacol.28, 111–114 (2005).
   PubMed Web of Science ®Google Scholar
• Schindehutte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson’s disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin. Neurol. Neurosurg.109, 188–191 (2006).
   PubMedGoogle Scholar
• Michelli F, Taubenslag N, Gatto E, Scorticati MC. Ziprasidone and psychosis in Parkinson’s disease. Clin. Neuropharmacol.28, 254 (2005).
   PubMedGoogle Scholar
• Friedman JH, Berman RM, Goetz CG et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov. Disord.21, 2078–2081 (2006).
   PubMed Web of Science ®Google Scholar
• Fernanadez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson’s disease: preliminary experience. Clinic. Neuropharmacol.27, 4–5 (2004).
   PubMedGoogle Scholar
• Barbato L, Monge A, Stocchi F, Nordera G. Melperone in the treatment of iatrogenic psychosis in Parkinson’s disease. Funct. Neurol.11, 201–207 (1996).
   PubMed Web of Science ®Google Scholar
• Friedman JH, Meltzer HY, van Kammen D et al. ACP 103 in the treatment of psychosis in Parkinson’s disease. Presented at: Parkinson's Study Group Annual Meeting on Parkinson’s Disease. Chicago, IL, USA, October 2006.
   Google Scholar
• Burn D, Emre M, McKeith I et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov. Disord.21, 1899–1907 (2006).
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease. N. Engl. J. Med.351, 2509–2518 (2004).
   PubMed Web of Science ®Google Scholar
• McKeith I, Del Ser T, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet356, 2031–2036 (2000).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov. Disord.20(10), 1255–1263 (2005).
   PubMed Web of Science ®Google Scholar
• Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord.20(2), 190–199 (2005).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J. Am. Geriatr. Soc.48(8), 938–942 (2000).
   PubMed Web of Science ®Google Scholar
• Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov. Disord.19(9), 1043–1049 (2004).
   PubMed Web of Science ®Google Scholar
• Marder K, Tang MX, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson’s disease. Arch. Neurol.52(7), 695–701 (1995).
   PubMed Web of Science ®Google Scholar
• Hughes TA, Ross HF, Musa S et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology54(8), 1596–1602 (2000).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol.60(3), 387–392 (2003).
   PubMed Web of Science ®Google Scholar
• de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch. Neurol.62(8), 1265–1269 (2005).
   PubMedGoogle Scholar
• Harhangi BS, de Rijk MC, van Duijn CM, Van Broeckhoven C, Hofman A, Breteler MM. APOE and the risk of PD with or without dementia in a population-based study. Neurology54(6), 1272–1276 (2000).
   PubMedGoogle Scholar
• Parsian A, Racette B, Goldsmith LJ, Perlmutter JS. Parkinson’s disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics79(3), 458–461 (2002).
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition). American Psychiatric Association, WA, USA (1994).
   Google Scholar
• Pillon B, Boller F, Levy R, Dubois B. Cognitive deficits and dementia in Parkinson’s disease. In: Handbook of Neuropsychology (2nd Edition). Boller F, Cappa S (Eds). Elsevier Science BV, Amsterdam, The Netherlands 311–371 (2001).
   Google Scholar
• McKeith IG, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology47(5), 1113–1124 (1996).
   PubMed Web of Science ®Google Scholar
• Cummings JL. In: Third International Workshop on Dementia with Lewy Bodies and Parkinson’s Disease Dementia. MedReviews, LLC, Newcastle upon Tyne, UK 31–34 (2003).
   Google Scholar
• Aarsland D, Ballard CG, Halliday G. Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity? J. Geriatr. Psychiatry Neurol.17(3), 137–145 (2004).
   PubMed Web of Science ®Google Scholar
• Perry EK, Curtis M, Dick DJ et al. Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry48(5), 413–421 (1985).
   PubMed Web of Science ®Google Scholar
• Perry EK, Irving D, Kerwin JM et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis. Assoc. Disord.7(2), 69–79 (1993).
   PubMed Web of Science ®Google Scholar
• Brown DF, Dababo MA, Bigio EH et al. Neuropathologic evidence that the Lewy body variant of Alzheimer disease represents coexistence of Alzheimer disease and idiopathic Parkinson disease. J. Neuropathol. Exp. Neurol.57(1), 39–46 (1998).
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch. Neurol.50(2), 140–148 (1993).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Morphological substrates of dementia in parkinsonism. A critical update. J. Neural Transm. (Suppl. 51), 57–82 (1997).
   Google Scholar
• Hurtig HI, Trojanowski JQ, Galvin J et al. α-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology54(10), 1916–1921 (2000).
   PubMed Web of Science ®Google Scholar
• Poewe W, Wolters E, Emre M et al. Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov. Disord.21, 456–461 (2006).
   PubMed Web of Science ®Google Scholar
• Ravina B, Putt M, Siderowf A et al. Donepezil in Parkinson’s disease: a randomized, double-blind, placebo-controlled, crossover study. J. Neurol. Neurosurg. Psychiatry76, 934–939 (2005).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomized controlled study. J. Neurol. Neurosurg. Psychiatry72, 708–712 (2002).
   PubMed Web of Science ®Google Scholar
• Leroi I, Brandt J, Reich SG et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int. J. Geriatr. Psychiatry19(1), 1–8 (2004).
   PubMed Web of Science ®Google Scholar
• Meagher DJ. Delirium: optimising management. Br. Med. J.322(7279), 144–149 (2001).
   PubMedGoogle Scholar
• Golden WE, Lavender RC, Metzer WS. Acute postoperative confusion and hallucinations in Parkinson disease. Ann. Intern. Med.111(3), 218–222 (1989).
   PubMed Web of Science ®Google Scholar
• Serrano-Duenas M, Bleda MJ. Delirium in Parkinson’s disease patients. A five-year follow-up study. Parkinsonism Relat. Disord.11(6), 387–392 (2005).
   PubMedGoogle Scholar
• Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson’s disease. Mov. Disord.13, 895–899 (1998).
   PubMed Web of Science ®Google Scholar
• Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin. Neuropharmacol.5, 183–194 (1982).
   PubMed Web of Science ®Google Scholar
• van Hilten JJ, Weggeman M, van der Welde EA, Kerkhof GA, van Dijk JG, Roos RAC. Sleep, excessive daytime sleepiness and fatigue in Parkinson’s disease. J. Neural Transm. Park. Dis. Sect.5, 235–244 (1993).
   Google Scholar
• Lees AS, Blackburn NA, Campbell VL. The nighttime problems of Parkinson’s disease. Clinic. Neuropharmacol.11, 512–519 (1988).
   PubMed Web of Science ®Google Scholar
• Borek LL, Kohn R, Friedman JH. Mood and sleep in Parkinson’s disease. J. Clin. Psychiatry67, 958–963 (2006).
   PubMed Web of Science ®Google Scholar
• Swift CG, Shapiro CM. ABC of sleep disorders. Sleep and sleep problems in elderly people. Br. Med. J.306, 1468–1471 (1993).
   PubMedGoogle Scholar
• Juri C, Chana P, Tapia J, Kunstmann C, Parrao T. Quetiapine for insomnia in Parkinson’s disease: results from an open-label trial. Clin. Neuropharmacol.28, 185–187 (2005).
   PubMedGoogle Scholar
• Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med.6, 459–466 (2005).
   PubMed Web of Science ®Google Scholar
• Maria B, Sophia S, Michalis M et al. Sleep breathing disorders in patients with idiopathic Parkinson’s disease. Respir. Med.97, 1151–1157 (2003).
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Kripke DF, Klauber MR et al. Morbidity, mortality and sleep-disordered breathing in community dwelling elderly. Sleep19, 277–282 (1996).
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Odin P, Serrano C. Restless legs syndrome and PD: a review of the evidence for a possible association. Neurology61, S49–S55 (2003).
   PubMed Web of Science ®Google Scholar
• Schenck CH, Hurwitz TD, Mahowald MW. Symposium: normal and abnormal REM sleep regulation: REM sleep behavior disorder: an update on a series of 96 patients and a review of the world literature. J. Sleep Res.2, 224–231 (1993).
   PubMedGoogle Scholar
• Borek LL, Kohn R, Friedman JH. Phenomenology of dreams in Parkinson’s disease. Mov. Disord.22, 198–202 (2007).
   PubMed Web of Science ®Google Scholar
• Gagnon JF, Bedard MA, Fantini ML et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease. Neurology59, 585–589 (2002).
   PubMed Web of Science ®Google Scholar
• Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain123, 331–339 (2000).
   PubMed Web of Science ®Google Scholar
• Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology67, 742–747 (2006).
   PubMedGoogle Scholar
• Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson’s disease. Mov. Disord.17, 775–781 (2002).
   PubMed Web of Science ®Google Scholar
• Sharf B, Moskovitz C, Lupton MD, Klawans HL. Dream phenomena induced by chronic levodopa therapy. J. Neural Transm.43, 143–151 (1978).
   PubMed Web of Science ®Google Scholar
• Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime sleepiness in Parkinson’s disease: is it the drugs or the disease? Neurology67, 853–858 (2006).
   PubMed Web of Science ®Google Scholar
• Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson’s disease: a community-based study. Mov. Disord.14, 922–927 (1999).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology57, 1392–1396 (2001).
   PubMed Web of Science ®Google Scholar
• Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology52, 1908–1910 (1999).
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson’s disease treatment. Lancet15, 1333–1334 (2000).
   Google Scholar
• Hagell P, Broman JE. Measurement properties and hierarchical item structure of the Epworth Sleepiness Scale in Parkinson’s disease. J. Sleep Res.16, 102–109 (2007).
   PubMed Web of Science ®Google Scholar
• Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov. Disord.18, 287–293 (2003).
   PubMed Web of Science ®Google Scholar
• Hogl B, Slaetu M, Brandauer E et al. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep25, 905–909 (2002).
   PubMed Web of Science ®Google Scholar
• Lou JS, Kearns G, Oken B, Sexton G, Nutt J. Exacerbated physical fatigue and mental fatigue in Parkinson’s disease. Mov. Disord.16(2), 190–196 (2001).
   PubMed Web of Science ®Google Scholar
• Friedman JH, Brown R, Comella C et al. Fatigue in Parkinson’s disease: a review. Mov. Disord.22, 297–308 (2006).
   Google Scholar
• Friedman J, Friedman H. Fatigue in Parkinson’s disease. Neurology43(10), 2016–2018 (1993).
   PubMed Web of Science ®Google Scholar
• van Hilten JJ, Hoogland G, van der Velde EA, Middelkoop HA, Kerkhof GA, Roos RA. Diurnal effects of motor activity and fatigue in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry56(8), 874–877 (1993).
   PubMed Web of Science ®Google Scholar
• Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an independent and persistent symptom in patients with Parkinson’s disease? Neurology63, 1908–1911 (2004).
   PubMed Web of Science ®Google Scholar
• Karlsen K, Larsen JP, Tandberg E, Jorgensen K. Fatigue in patients with Parkinson’s disease. Mov. Disord.14, 237–241 (1999).
   PubMed Web of Science ®Google Scholar
• Larsen JP, Karlsen K, Tandberg E. Clinical problems in non-fluctuating patients with Parkinson’s disease: a community-based study. Mov. Disord.15, 826–829 (2000).
   PubMedGoogle Scholar
• Shiffito G, Friedman JH, Oakes D et al. Fatigue in ELLDOPA. Presented at: World Congress Parkinson’s Disease, WA, USA, 22–26 February 2006.
   Google Scholar
• Roth T, Rye DB, Borchert LD, Bartlett C et al. Assessment of sleepiness and unintended sleep in Parkinson’s disease patients taking dopamine agonists. Sleep Med.4, 275–280 (2003).
   PubMed Web of Science ®Google Scholar
• Irvine D, Vincent L, Graydon JE et al. The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. Cancer Nurs.17, 367–378 (1994).
   PubMed Web of Science ®Google Scholar
• French MA. The clinical significance of tiredness. Can. Med. Assoc. J.82, 665–671 (1960).
   PubMedGoogle Scholar
• Norrelund N, Hollnagel H. Fatigue among 40-year olds. Ugeskr. Laeg.14, 1425–1429 (1979).
   Google Scholar
• Buchwald D, Sullivan JL, Komaroff AL. Frequency of chronic active Epstein–Barr virus infection in a general medical practice. JAMA257, 2303–2307 (1987).
   PubMed Web of Science ®Google Scholar
• Kroenke K, Wood DR, Mangelsdorff AD et al. Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome. JAMA260, 929–934 (1988).
   PubMed Web of Science ®Google Scholar
• Brown RG, Dittner A, Findley L, Wessely SC. The Parkinson Fatigue Scale. Parkinsonism Relat. Disord.1, 49–55 (2005).
   Google Scholar
• Garber CE, Friedman JH. Effects of fatigue on physical activity and function in patients with Parkinson’s disease. Neurology60(7), 1119–1124 (2003).
   PubMed Web of Science ®Google Scholar
• Smith AD, Zigmond MJ. Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. Exp. Neurol.184, 31–39 (2003).
   PubMed Web of Science ®Google Scholar
• Poulton NP, Muir GD. Treadmill training ameliorates dopamine loss but not behavioral deficits in hemi-parkinsonism rats. Exp. Neurol.193, 181–197 (2005).
   PubMed Web of Science ®Google Scholar
• Tillerson JL, Cohen AD, Philhower J et al. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J. Neurosci.15, 4427–4435 (2001).
   Google Scholar
• Cohen AD, Tillerson JL, Smith AD et al. Neuroprotective effects of prior limb use in 6-hydroxydopamine treated rats: possible role of GDNF. J. Neurochem.85, 299–305 (2003).
   PubMed Web of Science ®Google Scholar
• Nail LM. Fatigue in patients with cancer. Onocol. Nurs. Forum29, 537 (2002).
   PubMedGoogle Scholar
• Pucci E, Branas P, D’Amico R et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst. Rev.24, CD002818 (2007).
   Google Scholar
• Martinez-Martin P, Catalan M, Benito-Leon J et al. Impact of fatigue in Parkinson’s disease: the Fatigue Impact Scale for Daily Life (D-FIS). Qual. Life Res.15, 597–606 (2006).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Burns AM, Fava M. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J. Psychiatr. Res.40, 370–373 (2006).
   PubMed Web of Science ®Google Scholar
• Marin RS. Apathy: a neuropsychiatric syndrome. J. Neuropsychiatry Clin. Neurosci.3(3), 243–254 (1991).
   PubMed Web of Science ®Google Scholar
• Richard IH. Apathy does not equal depression in Parkinson disease: why we should care. Neurology67(1), 10–11 (2006).
   PubMed Web of Science ®Google Scholar
• McPherson S, Fairbanks L, Tiken S, Cummings JL, Back-Madruga C. Apathy and executive function in Alzheimer’s disease. J. Int. Neuropsychol. Soc.8(3), 373–381 (2002).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci.13(1), 42–49 (2001).
   PubMed Web of Science ®Google Scholar
• Levy ML, Cummings JL, Fairbanks LA et al. Apathy is not depression. J. Neuropsychiatry Clin. Neurosci.10(3), 314–319 (1998).
   PubMed Web of Science ®Google Scholar
• Kirsch-Darrow L, Fernandez HH, Marsiske M, Okun MS, Bowers D. Dissociating apathy and depression in Parkinson disease. Neurology67(1), 33–38 (2006).
   PubMed Web of Science ®Google Scholar
• Pluck GC, Brown RG. Apathy in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry73(6), 636–642 (2002).
   PubMed Web of Science ®Google Scholar
• Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb. Cortex16(7), 916–928 (2006).
   PubMed Web of Science ®Google Scholar
• Isella V, Melzi P, Grimaldi M et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson’s disease. Mov. Disord.17(2), 366–371 (2002).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Lim NG et al. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry67(4), 492–496 (1999).
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci.4(2), 134–139 (1992).
   PubMed Web of Science ®Google Scholar
• Funkiewiez A, Ardouin C, Caputo E et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry75(6), 834–839 (2004).
   PubMed Web of Science ®Google Scholar
• Drapier D, Drapier S, Sauleau P et al. Does subthalamic nucleus stimulation induce apathy in Parkinson’s disease? J. Neurol.253(8), 1083–1091 (2006).
   PubMed Web of Science ®Google Scholar
• Fogel BS. The significance of frontal system disorders for medical practice and health policy. J. Neuropsychiatry Clin. Neurosci.6(4), 343–347 (1994).
   PubMed Web of Science ®Google Scholar
• Thomas P, Clement JP, Hazif-Thomas C, Leger JM. Family, Alzheimer’s disease and negative symptoms. Int. J. Geriatr. Psychiatry16(2), 192–202 (2001).
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci.14(4), 461–462 (2002).
   PubMed Web of Science ®Google Scholar
• Okun MS, Heilman KM, Vitek JL. Treatment of pseudobulbar laughter after gamma knife thalamotomy. Mov. Disord.17(3), 622–624 (2002).
   PubMedGoogle Scholar
• Okun MS, Raju DV, Walter BL et al. Pseudobulbar crying induced by stimulation in the region of the subthalamic nucleus. J. Neurol. Neurosurg. Psychiatry75(6), 921–923 (2004).
   PubMedGoogle Scholar
• Schupbach WM, Chastan N, Welter ML et al. Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up. J. Neurol. Neurosurg. Psychiatry76(12), 1640–1644 (2005).
   PubMed Web of Science ®Google Scholar
• Schiffer R, Pope LE. Review of pseudobulbar affect including a novel and potential therapy. J. Neuropsychiatry Clin. Neurosci.17(4), 447–454 (2005).
   PubMed Web of Science ®Google Scholar
• Kaschka WP, Meyer A, Schier KR, Froscher W. Treatment of pathological crying with citalopram. Pharmacopsychiatry34(6), 254–258 (2001).
   PubMedGoogle Scholar
• Brooks BR, Thisted RA, Appel SH et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology63(8), 1364–1370 (2004).
   PubMed Web of Science ®Google Scholar
• Panitch HS, Thisted RA, Smith RA et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann. Neurol.59(5), 780–787 (2006).
   PubMed Web of Science ®Google Scholar
• Voon V. Repetition, repetition and repetition: compulsive and punding behaviors in Parkinson’s disease. Mov. Disord.19, 367–370 (2004).
   PubMed Web of Science ®Google Scholar
• Friedman JH. Punding on levodopa. Biol. Psychiatry36, 350–351 (1994).
   PubMed Web of Science ®Google Scholar
• Molina J, Sainz-Artiga MJ, Fraile A et al. Pathologic gambling in Parkinson’s disease: a behavioral manifestation of pharmacological treatments? Mov. Disord.15, 869–872 (2000).
   PubMed Web of Science ®Google Scholar
• Miwa H, Morita S, Nakanishi I, Kondo T. Stereotyped behaviors or punding after quetiapine administration in Parkinson’s disease. Parkinsonism Relat. Disord.19, 177–180 (2005).
   Google Scholar
• Evans AH, Katzenschlager R, Paviour D et al. Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov. Disord.19, 397–405 (2004).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Potenza MN. Impulse control disorders in Parkinson’s disease. Curr. Neurol. Neurosci. Rep.6, 302–306 (2006).
   PubMed Web of Science ®Google Scholar
• Tippmann-Peikert M, Park JH, Boeve BF et al. Pathological gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology68, 301–303 (2007).
   PubMed Web of Science ®Google Scholar
• Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behavior: emergence secondary to treatment of Parkinson’s disease with dopaminergic agents. Depress. Anxiety11, 185–186 (2000).
   PubMed Web of Science ®Google Scholar
• Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology61, 422–423 (2003).
   PubMed Web of Science ®Google Scholar
• Kurlan R. Disabling repetitive behaviors in Parkinson disease. Mov. Disord.19, 433–437 (2004).
   PubMed Web of Science ®Google Scholar